How Much Does Lipfendra Cost?

Published on July 17, 2026 | Written by Alec Pow
This article was researched using 12 sources. See our methodology and corrections policy.

Lipfendra is a new prescription cholesterol tablet from Merck. Its announced U.S. list price is $10.50 per tablet, which comes to $315 for a 30-day supply before insurance discounts, manufacturer support, or pharmacy benefit adjustments.

The amount charged at the pharmacy may be far lower than the list price, but Lipfendra entered the market only after its July 16, 2026 FDA approval. Many insurers had not yet published formulary placement, prior authorization rules, or copay tiers when the drug was announced.

Lipfendra spending is measured per daily tablet, monthly fill, and year of treatment. Insurance tier, deductible status, pharmacy network, refill size, and related medical visits can change the patient total.

A cash-paying patient faces about $315 per month at the announced list price, with the final insured amount still dependent on plan rules.

How Much Does Lipfendra Cost?

Jump to sections

• Daily list price: $10.50 (at $30 per hour, earning that amount would take about 21 minutes, before taxes)
• 30-day list price: $315
• Calculated 12-month list-price total: $3,780
• Launch date: July 2026
• Dosing schedule: one tablet each day

What this is in plain terms

Lipfendra is the brand name for enlicitide, an oral medicine that blocks PCSK9. That protein affects the number of LDL receptors available to clear LDL cholesterol from the bloodstream. The FDA approved Lipfendra for adults with hypercholesterolemia, including adults with heterozygous familial hypercholesterolemia.

The medicine is taken as a tablet rather than injected. That separates it from Repatha and Praluent, which patients or caregivers inject, and Leqvio, which a health professional administers. Lipfendra also differs from statins and ezetimibe because it acts through another biological pathway. It is not an over-the-counter supplement, a replacement for diet and exercise, or a medicine that should be selected without a prescriber. The purchase involves a recurring prescription plus any insurance approval and follow-up care required by the clinician.

Lipfendra costs per month and year

Merck set Lipfendra’s launch list price at $10.50 (about 21 minutes at $30 per hour) per daily pill, or about $315 for 30 tablets, according to a company spokesperson cited in the launch pricing report. This is the amount before rebates, insurer negotiations, pharmacy contracts, coupons, or assistance programs. It is not a guaranteed pharmacy quote.

A full year at the stated monthly amount is $3,780. The arithmetic is $315 multiplied by 12 monthly fills. A tablet-based calculation produces the same result for a 360-day supply, since $10.50 multiplied by 360 equals $3,780. Calendar-year spending could be slightly different when refill dates, package sizes, or missed doses change the number of tablets dispensed.

Payment measure	Amount before coverage	What it represents
One tablet	$10.50	One daily dose at launch list price
30-day fill	$315	Thirty tablets before discounts
Three 30-day fills	$945	Three months at list price
Twelve 30-day fills	$3,780	One calculated year at list price

Insurance vs self-pay

A self-pay customer may face an amount near the $315 (about 1.3 full-time workdays at $30 per hour) monthly list price during the launch period, but retail pharmacies can set different cash charges. Reuters reported that Lipfendra would become available within weeks of approval and confirmed the $10.50 daily and roughly $315 monthly figures in its July 2026 approval coverage. Patients should request the pharmacy’s current cash quote rather than treating list price as a fixed checkout amount.

Commercial insurance may replace the cash charge with a copay or coinsurance amount. A deductible can leave the member paying much of the negotiated price early in the plan year. Placement on a nonpreferred or specialty tier can raise the patient share. A plan may also require prior authorization, proof of earlier cholesterol therapy, or a documented LDL-C result before approving payment.

Medicare and Medicaid members cannot assume that a commercial manufacturer coupon will apply. Government-program coverage and assistance eligibility follow separate rules. Early launch formularies may also lag the FDA approval date. Patients can ask the insurer whether Lipfendra is covered, which benefit processes the claim, what tier applies, and whether approval is needed before the first fill.

Dosage and refill timing

The FDA states that Lipfendra is taken by mouth once daily. The approved medicine is used with diet and exercise to reduce LDL-C in adults with high cholesterol or heterozygous familial hypercholesterolemia, as described in the FDA approval notice. One tablet a day creates a steady tablet-count expense rather than an injection or office-administration charge.

A 30-day fill uses 30 tablets. Three separate 30-day fills equal $945 at list price because $315 multiplied by three is $945. A 90-day pharmacy fill could contain the same number of tablets as three monthly fills, but the patient charge is controlled by the plan’s mail-order and extended-supply rules. A three-month copay is not always three times a monthly copay.

The prescribing instructions also affect practical use. Lipfendra must be taken under the food conditions stated in the label. A missed or incorrectly timed dose should be handled according to the prescribing information and advice from the patient’s clinician or pharmacist, not by taking extra tablets. Anyone comparing refill prices should verify quantity, days supplied, network status, and whether the quote uses insurance.

Medical visits and tests

The pharmacy payment covers the medicine. It does not include a clinician’s evaluation, cholesterol testing, medication review, or treatment of an adverse reaction. A patient may have an appointment before the first prescription and another visit after therapy begins. Those services are billed through the medical benefit or paid directly to the provider.

A lipid panel may be ordered to document the starting LDL-C level or measure response. The timing belongs to the treatment plan. Patients can ask the laboratory whether the order is in network and whether the charge includes collection fees. The price of a cardiology visit may also matter when a specialist manages the prescription rather than a primary care clinician.

Possible extra charges include the prescriber visit, lipid testing, pharmacy delivery, and care needed after a side effect. These charges are separate from the $315 monthly list price.

The FDA-approved label lists the indication, administration instructions, warnings, and adverse reactions in the full prescribing information. The label does not set office or laboratory charges. Those amounts come from the provider, laboratory, insurance contract, and location.

What three different patients may pay

Cash case. A patient without usable drug coverage buys one 30-day supply near the announced list price. The medicine portion is $315. Twelve equal fills would total $3,780. A pharmacy could quote another cash amount, and appointments or testing would be added separately.

Commercial insurance case. A member has Lipfendra on the plan formulary after prior authorization. The insurer applies a copay or coinsurance amount instead of charging the full cash figure. The exact payment cannot be stated without the plan’s tier, deductible, network, and assistance rules. The Wall Street Journal reported the $315 monthly retail figure and noted that insured patients were expected to pay less in its approval and pricing report.

Medicare case. A Medicare Part D enrollee checks the plan formulary after the drug reaches pharmacies. The member’s payment can change during the year as deductible and benefit phases apply. Commercial copay offers may exclude federal health program beneficiaries. The enrollee can compare the plan price with any lawful cash-access route, but a cash purchase may not count toward Part D out-of-pocket spending.

Lipfendra vs other PCSK9 medicines

Lipfendra’s announced list-price total is $3,780 per year when calculated from twelve $315 fills. Its payment structure resembles a recurring pharmacy prescription. Repatha is an injectable PCSK9 medicine, and Amgen states that an eligible commercially insured patient may pay as little as $5 per month through the Repatha copay program. Eligibility limits apply, so that figure is not available to every patient.

Amgen also announced a direct cash price of $239 per month for Repatha through AmgenNow. At that rate, twelve months equal $2,868, since $239 multiplied by 12 is $2,868. The terms and access route appear in the manufacturer’s direct-sale announcement.

Leqvio is administered by a health professional and may be processed through the medical benefit. Novartis lists an uninsured price of $3,587.73 per dose on its savings and insurance page. Administration charges may be separate. Route, dosing schedule, insurance channel, clinical indication, and outcomes evidence differ, so price alone does not establish which medicine fits a patient.

Worked annual budget

A cash budget based only on Lipfendra’s launch list price starts with 12 fills. The medicine calculation is 12 multiplied by $315, producing $3,780. A three-month checkpoint would be three multiplied by $315, or $945. Six months would be $1,890. The budget should then add the patient’s verified office and laboratory quotes rather than inserting national estimates that may not match the provider.

• Months one through three: $945
• Months four through six: $945
• Months seven through nine: $945
• Months ten through twelve: $945
• Annual medicine total: $3,780
• Visits and laboratory services: add the patient’s quoted amounts

Makes sense if

• A licensed prescriber has selected Lipfendra for added LDL-C reduction.
• The insurance plan covers the medicine at a manageable member payment.
• A daily oral tablet suits the prescribed regimen better than an injection schedule.
• The patient can follow the label’s food and timing instructions.

Doesn’t make sense if

• The buyer is seeking a nonprescription cholesterol product.
• The plan excludes Lipfendra and the full cash payment is unaffordable.
• A covered alternative meets the prescriber’s clinical goal at a lower patient charge.
• The patient expects the drug payment to include medical visits and laboratory work.

Treatment selection requires a clinical discussion. The insurance and prescription cost structure seen with other branded medicines also shows why list price, pharmacy price, and out-of-pocket payment are separate figures.

What we verified

• Checked the approval date and approved population in the Merck approval release.
• Confirmed the patient description and oral use in the patient information sheet.
• Cross-referenced the launch price and availability timing through the Associated Press report.
• Verified that enlicitide was developed as an oral PCSK9 inhibitor in the CORALreef trial release.

Article Highlights

• Lipfendra’s announced list price is $315 for 30 tablets.
• Twelve equal monthly fills total $3,780 before discounts.
• Insurance placement and prior authorization can change the pharmacy payment.
• Office visits and lipid tests are billed apart from the prescription.
• Cash, commercial insurance, and Medicare cases can produce different totals.
• Patients should compare quantity, network status, and benefit type on every quote.

Answers to Common Questions

How much is Lipfendra without insurance?

The announced U.S. list price is $315 for a 30-day supply. A retail pharmacy may charge a different cash amount.

How much does Lipfendra cost for a year?

Twelve 30-day fills at $315 each equal $3,780. Medical visits and laboratory services are separate.

Will insurance cover Lipfendra?

Coverage depends on the insurer’s formulary, tier, deductible, network, and authorization policy. The drug was approved in July 2026, so some plan records may take time to update.

Is Lipfendra cheaper than Repatha or Leqvio?

The answer changes by insurance and access program. Lipfendra has a $315 monthly list price, Repatha has a cited $239 monthly direct-pay route, and Leqvio lists $3,587.73 per dose for uninsured patients. Their dosing and billing routes differ.

Does the Lipfendra price include cholesterol tests?

No. Laboratory testing and clinician appointments are separate services. Patients can request written estimates from the laboratory and prescriber before treatment begins.